Apex Biotechnology Receivables

Apex Biotechnology posts a receivables of $410M as of June 2026. That compares with $420M in the prior-year period — down 2.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Apex Biotechnology's receivables was $420M. The latest reading is $410M — a 2.4% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Apex Biotechnology's financial statement story. At $410M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 1733.TW's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Apex Biotechnology's other metric pages and overview cover the third.

Judging Apex Biotechnology against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $410M here, then scan peer and history charts to see if the gap is persistent.